N-methyl-5,6,7,8-tetrahydronaphthalen-2-amine | 15067-39-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: N-methyl-5,6,7,8-tetrahydronaphthalen-2-amine
• CAS: 15067-39-7
• 化学式: C₁₁H₁₅N
• 分子量: 161.247
• InChiKey: RTWRRNODKQLJFY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 戊醇 、 sodium 作用下， 生成 N-methyl-5,6,7,8-tetrahydronaphthalen-2-amine
  参考文献：
  名称：

  Smith, Journal of the Chemical Society, 1904, vol. 85, p. 735

  摘要：

  DOI：

文献信息

• A Metal‐Free Direct Arene C−H Amination
  作者：Tao Wang、Marvin Hoffmann、Andreas Dreuw、Edina Hasagić、Chao Hu、Philipp M. Stein、Sina Witzel、Hongwei Shi、Yangyang Yang、Matthias Rudolph、Fabian Stuck、Frank Rominger、Marion Kerscher、Peter Comba、A. Stephen K. Hashmi

  DOI：10.1002/adsc.202100236

  日期：2021.6.8

  The synthesis of aryl amines via the formation of a C−N bond is an essential tool for the preparation of functional materials, active pharmaceutical ingredients and bioactive products. Usually, this chemical connection is only possible by transition metal-catalyzed reactions, photochemistry or electrochemistry. Here, we report a metal-free arene C−H amination using hydroxylamine derivatives under benign

  通过形成 CN 键合成芳胺是制备功能材料、活性药物成分和生物活性产品的重要工具。通常，这种化学连接只能通过过渡金属催化的反应、光化学或电化学来实现。在这里，我们报告了在良性条件下使用羟胺衍生物进行的无金属芳烃 C-H 胺化。即使在存在各种官能团的情况下，胺化试剂 TsONHR 和芳烃底物之间的电荷转移相互作用也能实现芳烃的化学选择性胺化。氧气对于有效转化至关重要，其对电子转移步骤的加速作用已通过实验证明。此外，
• SUBSTITUTED NAPHTHYRIDINES AND USE THEREOF AS MEDICINES
  申请人：Hoffmann Matthias

  公开号：US20110201608A1

  公开（公告）日：2011-08-18

  The invention relates to new substituted naphthyridines of formula 1, as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, wherein R 1 denotes a group A selected from among —O—R 3 , —NR 3 R 4 , —CR 3 R 4 R 5 , -(ethyne)-R 3 , —S—R 3 , —SO—R 3 and SO 2 —R 3 or R 1 denotes a group B selected from among C 6-10 -aryl, five- to ten-membered, mono- or bicyclic heteroaryl with 1-3 heteroatoms selected independently of one another from among N, O and S; while this heteroaryl is linked to the structure according to formula 1 via either a C atom or an N atom, three- to ten-membered, mono- or bicyclic, saturated or partially saturated heterocyclic group with 1-3 heteroatoms selected independently of one another from among N, O and S, while this heterocyclic group is linked to the structure according to formula 1 via either a C atom or an N atom, and 5- to 11-membered spiro group which may optionally contain 1, 2 or 3 heteroatoms selected independently of one another from among N, O and S, while this spiro group is linked to the structure according to formula 1 via either a C atom or an N atom, while this group B may optionally be substituted as described in claim 1 and wherein R 2 is and R 3 , R 4 , R 5 , R 6 , R 6′ , R 7 , R 8 , R 9 , R 10 , V, n and m may have the meanings given in claim 1 , as well as pharmaceutical compositions containing these compounds.

  该发明涉及公式1的新取代萘啉类化合物，以及其药理学上可接受的盐、对映体、对映异构体、外消旋体、水合物或溶剂合物，其中R1表示从以下选取的A基团，包括—O—R3、—NR3R4、—CR3R4R5、-(乙炔)-R3、—S—R3、—SO—R3和SO2—R3，或R1表示从以下选取的B基团，包括C6-10-芳基、含有1-3个异原子（N、O和S）的五至十元杂环芳基，而此杂环芳基通过碳原子或氮原子与公式1中的结构连接，含有1-3个异原子（N、O和S）的三至十元杂环饱和或部分饱和环族基团，而此杂环基团通过碳原子或氮原子与公式1中的结构连接，以及可能含有1、2或3个异原子（N、O和S）的五至十一元螺环基团，而此螺环基团通过碳原子或氮原子与公式1中的结构连接，其中该B基团可以选择地按照权利要求1中所述进行取代，R2为，R3、R4、R5、R6、R6′、R7、R8、R9、R10、V、n和m的含义如权利要求1中所述，以及含有这些化合物的药物组合物。
• Synthesis of <i>N</i>-Alkyl Anilines from Arenes via Iron-Promoted Aromatic C–H Amination
  作者：Eric Falk、Valentina C. M. Gasser、Bill Morandi

  DOI：10.1021/acs.orglett.1c00099

  日期：2021.2.19

  We report both an intermolecular C–H amination of arenes to access N-methylanilines and an intramolecular variant for the synthesis of tetrahydroquinolines. A newly developed, highly electrophilic aminating reagent was key for the direct synthesis of unprotected N-methylanilines from simple arenes. The reactions display a broad functional group tolerance and employ catalytic amounts of a benign iron

  我们报告了芳烃的分子间CH氨基化反应以访问N-甲基苯胺和合成四氢喹啉的分子内变体。新型开发的高度亲电胺化试剂是从简单的芳烃直接合成未保护的N-甲基苯胺的关键。反应显示出宽泛的官能团耐受性，并在温和的反应条件下使用催化量的良性铁盐。
• [EN] COMPOSITIONS FOR PREVENTING OR TREATING DRY EYE<br/>[FR] COMPOSITIONS POUR LA PRÉVENTION OU LE TRAITEMENT DE LA SÉCHERESSE OCULAIRE
  申请人：CHONG KUN DANG PHARMACEUTICAL CORP

  公开号：WO2019199034A1

  公开（公告）日：2019-10-17

  The present invention relates to a pharmaceutical composition for preventing or treating dry eye, containing a compound represented by a formula I, an optical isomer thereof or a pharmaceutically acceptable salt thereof as an effective component, as well as a treatment method using the compound, and use of the compound in the manufacture of a medicament for treating dry eye. The pharmaceutical composition according to the present invention shows an excellent effect of preventing or treating dry eye.

  本发明涉及一种用于预防或治疗干眼症的药物组合物，包含一种由式I表示的化合物、其光学异构体或其药用可接受盐作为有效成分，以及使用该化合物的治疗方法，以及将该化合物用于制造治疗干眼症的药物。根据本发明的药物组合物显示出预防或治疗干眼症的优异效果。
• QUINOLINE COMPOUNDS FOR INCREASING INSULINE RELEASE
  申请人：Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

  公开号：EP3246028A1

  公开（公告）日：2017-11-22

  The present invention relates to a class of quinoline compounds that act as insulin secretagogues, i.e., induce insulin secretion from beta cells. The present compounds may be used to induce divalent calcium cation influx in pancreatic beta-cells or to activate voltage-dependent calcium channels in pancreatic beta-cells. The present invention further relates to compounds for use in the treatment of diabetes.

  本发明涉及一类可作为胰岛素促泌剂，即诱导β细胞分泌胰岛素的喹啉化合物。本发明化合物可用于诱导胰腺β细胞中的二价钙阳离子流入或激活胰腺β细胞中的电压依赖性钙通道。本发明进一步涉及用于治疗糖尿病的化合物。